Takeda presents Phase III ADVANCE-CIDP 1 clinical trial results investigating Hyqvia in CIDP
Japan’s largest drugmaker Takeda (TYO: 4502) has released full results from the pivotal Phase III ADVANCE-CIDP 1 clinical trial investigating Hyqvia (immune globulin infusion 10% [human] with recombinant human hyaluronidase) as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).
These results showed a clinically-significant reduction in relapse rate with Hyqvia versus placebo (9.7% versus 31.4%, respectively; p = 0.0045) and other analysis showed delayed time to relapse with Hyqvia vs placebo. The company also observed favorable data across other endpoints from the study and favorable tolerability. These findings were presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting in Copenhagen, Denmark on June 20, 2023, and simultaneously published in the Journal of the Peripheral Nervous System (JPNS).#
$8.8 billion market potential
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze